Font size
- 1 2 3 + Font size

click to adjust

Page tools
. Advanced search

A Targeted Approach to HealthCare

Bayer HealthCare Pharmaceuticals' goal is to discover products that will improve human health worldwide by diagnosing, preventing and treating diseases. As a specialty pharmaceutical company, we focus our efforts where we can have the most impact.

For more than 100 years, Bayer has been dedicated to developing, manufacturing and marketing pharmaceuticals. Built on the company's long history of providing medicines that healthcare providers and patients can trust, Bayer is one of the most recognized brands in health care.

Bayer News Releases

21 July 2014

9 July 2014
The Life Raft Group and Bayer HealthCare Present GIST Awareness Day on Sunday, July 13

26 June 2014
Bayer and HealthyWomen Launch Family Size Matters to Help Raise Awareness on Family Planning for Women Who are Done Having Children

23 June 2014
Bayer HealthCare and Dimension Therapeutics to Develop Novel Gene Therapy for Hemophilia A

3 June 2014
Bayer to Support National Press Foundation's "Cancer Issues 2014" Educational Program

14 May 2014
Data from Bayer Oncology Portfolio and Pipeline to be Presented at ASCO 2014

12 May 2014
FDA Approves Bayer's Kogenate® FS Antihemophilic Factor VIII (recombinant) for Routine Prophylaxis in Adults with Hemophilia A

9 May 2014
Bayer Receives National Organization of Rare Disorders (NORD) Honor at "Portraits of Courage" Celebration

6 May 2014
Bayer to acquire consumer care business of US-based Merck & Co., Inc. and to engage in strategic pharma cooperation in the field of sGC modulators

24 April 2014
Bayer Receives CancerCare® Honor at 70th Anniversary Celebration Gala

23 April 2014
Phase 3 DECISION Trial of NEXAVAR (sorafenib) in Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Cancer Refractory to Radioactive Iodine Published in The Lancet

22 April 2014
FDA Grants Orphan Drug Designation for Bayer's Investigational Ciprofloxacin DPI (Dry Powder for Inhalation) for Treatment of Non-Cystic Fibrosis Bronchiectasis

11 April 2014
Bayer Launches New Educational Online Resource for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

2 April 2014
Bayer Initiates Phase 3 Trial of Xofigo® (radium Ra 223 dichloride) Injection in Combination with Abiraterone Acetate for Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Bone Predominant Metastatic Castration-Resistant Prostate Cancer


Press Release Archive


Further Information

Clinical Trials

Information about clinical studies is available at

Copyright © Bayer Healthcare Pharmaceuticals